{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T14:27:41Z","timestamp":1754144861718,"version":"3.41.2"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Backgrounds<\/jats:title><jats:p>Rifampicin-resistant tuberculosis (RR-TB) remains a major challenge to global TB control efforts. In Fujian Province, Southeast China, where RR-TB prevalence has been notably high, understanding epidemiological trends and treatment outcomes is crucial for optimizing interventions. This study aimed to analyze RR-TB characteristics, resistance patterns, and treatment outcomes to inform evidence-based control strategies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>An observational study was conducted utilizing data from China\u2019s National Tuberculosis Information Management System, focusing on bacteriologically confirmed tuberculosis cases reported in Fujian Province during 2019\u20132024. Epidemiological characteristics, drug resistance and outcomes of RR-TB were described as frequency (n) and percentage (%). Risk factors for unsuccessful outcomes were assessed using univariate and multivariate logistic regression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 1,368 RR-TB patients were detected, with an overall resistance rate of 3.7%. The RR rate showed a steady decline year by year (<jats:italic>\u03c7<jats:sup>2<\/jats:sup><\/jats:italic>\u202f=\u202f76.214, <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001), mainly due to the decrease in new TB cases (<jats:italic>\u03c7<jats:sup>2<\/jats:sup><\/jats:italic>\u202f=\u202f60.966, <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001). RR-TB patients exhibited higher co-resistance to isoniazid (71.9% vs. 6.3%, <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001) and ofloxacin (29.8% vs. 1.8%, <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001) compared to rifampicin-sensitive TB. Of 1,056 RR-TB patients initiated on treatment, 720 had outcome data, revealing a low success rate (58.6%) due to high loss to follow-up (31.1%) and mortality (9.3%). Multivariate analysis identified male sex (<jats:italic>AOR<\/jats:italic>\u202f=\u202f1.67, <jats:italic>95%<\/jats:italic> CI: 1.11\u20132.52, <jats:italic>p<\/jats:italic>\u202f=\u202f0.014), age \u226545\u202fyears (<jats:italic>AOR<\/jats:italic>\u202f=\u202f2.27, <jats:italic>95% CI:<\/jats:italic> 1.58\u20133.26, <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001), high-risk group status (<jats:italic>AOR<\/jats:italic>\u202f=\u202f1.42, <jats:italic>95% CI<\/jats:italic>: 1.04\u20131.94, <jats:italic>p<\/jats:italic>\u202f=\u202f0.026), and occupation as farmer\/worker (<jats:italic>AOR<\/jats:italic>\u202f=\u202f2.17, <jats:italic>95% CI<\/jats:italic>: 1.10\u20134.26, <jats:italic>p<\/jats:italic>\u202f=\u202f0.025) as independent risk factors of unsuccessful treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Fujian Province has demonstrated a steady decline in rifampicin resistance rates, primarily driven by reductions in new TB cases. However, treatment inclusion rate and success rate remains suboptimal, highlighting the need for targeted interventions\u2014including enhanced adherence support, intensive follow-up, and adverse event management\u2014particularly for high-risk groups such as older males and manual laborers. These findings can guide tailored strategies to further reduce RR-TB burden in similar settings.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2025.1611459","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T05:35:55Z","timestamp":1752644155000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Rifampicin-resistant tuberculosis in Fujian Province, Southeast China: a retrospective analysis of drug resistance screening and treatment outcomes, 2019\u20132024"],"prefix":"10.3389","volume":"13","author":[{"given":"Yinfa","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhisong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shufang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiquan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongming","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanqin","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"volume-title":"Global tuberculosis report 2024","year":"2024","key":"ref1"},{"volume-title":"Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. WHO\/HTM\/TB\/2014.11","year":"2014","key":"ref2"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1128\/AAC.01024-12","article-title":"Study of the rifampin monoresistance mechanism in Mycobacterium tuberculosis","volume":"57","author":"Pang","year":"2012","journal-title":"Antimicrob Agents CH"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1089\/mdr.2009.0054","article-title":"Microarray analysis of efflux pump genes in multidrug-resistant Mycobacterium tuberculosis during stress induced by common anti-tuberculous drugs","volume":"16","author":"Gupta","year":"2010","journal-title":"Microb Drug Resist"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e02220-16","DOI":"10.1128\/AAC.02220-16","article-title":"Acquisition of rifampin resistance in pulmonary tuberculosis","volume":"61","author":"Kayigire","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"ref6","first-page":"8","volume-title":"Standardized training course for the prevention and treatment of multidrug-resistant tuberculosis","author":"Chen","year":"2015"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"964","DOI":"10.3969\/j.issn.1000-6621.2019.09.010","article-title":"Drug affordability study in drug-resistant tuberculosis patients: base the cost of treatment","volume":"41","author":"Shen","year":"2019","journal-title":"Chin J Antituberc."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3969\/j.issn.1000-6621.2021.09.012","article-title":"Analysis of the drug resistance surveillance results of Mycobacterium tuberculosis in Fujian Province from 2016 to 2019","volume":"43","author":"Lin","year":"2021","journal-title":"Chin J Antituberc."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.19982\/j.issn.1000-6621.20240336","article-title":"Historical evolution and prospect of rifampicin-resistant tuberculosis prevention and control in China","volume":"46","author":"Ruan","year":"2024","journal-title":"Chin J Antituberc."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"70","DOI":"10.13604\/j.cnki.46-1064\/r.2025.01.12","article-title":"Rifampicin resistance in tuberculosis patients in Xinjiang Uygur autonomous region, 2018-2023","volume":"25","author":"Wang","year":"2025","journal-title":"Chin J Trop Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.3969\/j.issn.1000-6621.2021.11.014","article-title":"Analysis of drug resistance surveillance results of Mycobacterium tuberculosis in Gansu Province from 2014 to 2017","volume":"43","author":"Li","year":"2021","journal-title":"Chin J Antituberc."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"687","DOI":"10.19982\/j.issn.1000-6621.20220028","article-title":"Analysis of monitoring result of tuberculosis drug resistance in Guangdong Province from 2016 to 2020","volume":"44","author":"Chen","year":"2022","journal-title":"Chin J Antituberc"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"848","DOI":"10.12138\/j.issn.1671-9638.20244933","article-title":"Rifampicin resistance and its influencing factors in re-treated pulmonary tuberculosis patients in Chongqing City from 2018 to 2022","volume":"23","author":"Lei","year":"2024","journal-title":"Chin J Infect Control"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"949","DOI":"10.3760\/cma.j.cn112338-20221011-00870","article-title":"Analysis of tuberculosis epidemiological characteristics and drug resistance among the floating population in Beijing in 2019","volume":"44","author":"Yang","year":"2023","journal-title":"Chin J Epidemiol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3784\/jbjc.202208120359","article-title":"Characteristics of multidrug-resistant \/rifampicin-resistant tuberculosis patients and factors associated with treatmenteffect in Hubei, 2015\u22122021","volume":"38","author":"Yang","year":"2023","journal-title":"Dis Surveill"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1186\/s12879-024-09976-9","article-title":"Epidemiological characteristics, diagnosis and treatment effect of rifampicin-resistant pulmonary tuberculosis (RR-PTB) in Guizhou Province","volume":"24","author":"Zhou","year":"2024","journal-title":"BMC Infect Dis"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41579-024-01025-1","article-title":"Drug-resistant tuberculosis: a persistent global health concern","volume":"22","author":"Farhat","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1800544","DOI":"10.1183\/13993003.00544-2018","article-title":"Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa","volume":"51","author":"Olayanju","year":"2018","journal-title":"Eur Respir J"},{"volume-title":"Global tuberculosis report 2020","year":"2020","key":"ref19"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e1004749","DOI":"10.1371\/journal.pcbi.1004749","article-title":"The role of adherence and retreatment in de novo emergence of MDR-TB","volume":"12","author":"Cadosch","year":"2016","journal-title":"PLoS Comput Biol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1186\/s12913-021-07057-0","article-title":"Causes of multidrug-resistant tuberculosis from the perspectives of health providers: challenges and strategies for adherence to treatment during the COVID-19 pandemic in Brazil","volume":"21","author":"Souza","year":"2021","journal-title":"BMC Health Serv Res"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e0198091","DOI":"10.1371\/journal.pone.0198091","article-title":"Prevalence and patterns of rifampicin and isoniazid resistance conferring mutations in Mycobacterium tuberculosis isolates from Uganda","volume":"13","author":"Kigozi","year":"2018","journal-title":"PLoS One"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3969\/j.issn.1000-6621.2014.06.009","article-title":"Cross-resistance of ofloxacin-resistant Mycobacterium tuberculosis to five fluoroquinolones","volume":"6","author":"Wang","year":"2014","journal-title":"Chin J Antituberc."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"422","DOI":"10.3784\/jbjc.202311240633","article-title":"Impact of World Health Organization-recommended multidrug-resistant\/rifampicin-resistant tuberculosis treatmentregimen on tuberculosis epidemic in China based on a dynamic model","volume":"39","author":"Wang","year":"2024","journal-title":"Dis Surveill."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3760\/cma.j.cn112338-20240802-00472","article-title":"IRifampicin-resistant tuberculosis prevention and control in Jiangsu Province from 2013 to 2023","volume":"46","author":"Ding","year":"2025","journal-title":"Chin J Epidemiol."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3760\/cma.j.cn112338-20240702-00394","article-title":"Analysis on adverse treatment outcome of rifampicin-resistant tuberculosis patients and influencing factors in 9 provinces in China, 2017-2021","volume":"46","author":"Sun","year":"2025","journal-title":"Chin J Epidemiol."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e002186","DOI":"10.1136\/bmjresp-2023-0021865","article-title":"Why do patients with DR-TB do not complete their treatment? Findings of a qualitative study from Pakistan","volume":"11","author":"Abubakar","year":"2024","journal-title":"BMJ Open Respir Res"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/s12890-021-01735-9","article-title":"Determinant factors for loss to follow-up in drug-resistant tuberculosis patients: the importance of psycho-social and economic aspects","volume":"21","author":"Soedarsono","year":"2021","journal-title":"BMC Pulm Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/j.1532-5415.2011.03369.x","article-title":"Tuberculosis in older adults in the United States, 1993-2008","volume":"59","author":"Pratt","year":"2011","journal-title":"J Am Geriatr Soc"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"410","DOI":"10.19982\/j.issn.1000-6621.20240456","article-title":"Analysis of the treatment outcomes and influencing factors of rifampicin-resistant pulmonary tuberculosis patients aged 65 and above in China from 2015 to 2021","volume":"47","author":"Li","year":"2025","journal-title":"Chin J Antituberc."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.19982\/j.issn.1000-6621.20240215","article-title":"Treatment outcomes and influencing factors in elderly patients with multidrug-resistant\/rifampicin-resistant pulmonary tuberculosis: a nationa lmulticenter, retrospective cohort study","volume":"46","author":"Ye","year":"2024","journal-title":"Chin J Antituberc."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.2147\/IDR.S365394","article-title":"Multidrug-resistant tuberculosis treatment outcome and associated factors at the University of Gondar Comprehensive Specialized Hospital: a ten-year retrospective study","volume":"15","author":"Belachew","year":"2022","journal-title":"Infect Drug Resist"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.cmi.2023.12.001","article-title":"Treatment outcomes and risk factors for an unsuccessful outcome among patients with highly drug-resistant tuberculosis in Ukraine","volume":"30","author":"Pedersen","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"256","DOI":"10.13668\/j.issn.1006-9070.2023.03.004","article-title":"The treatment outcomes and influencing factors of rifampicin-resistant pulmonary tuberculosis patients in Jiangsu Province, 2011-2020","volume":"34","author":"Yu","year":"2023","journal-title":"Jiangsu J Prev Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3784\/jbjc.202303170106","article-title":"Treatment outcomes of 1165 patients with multidrug-resistant and extensively drug-resistant pulmonary tuberculosis and influencing factors","volume":"39","author":"Wang","year":"2024","journal-title":"Dis Surveill."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1611459\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T05:36:08Z","timestamp":1752644168000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1611459\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":35,"alternative-id":["10.3389\/fpubh.2025.1611459"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2025.1611459","relation":{},"ISSN":["2296-2565"],"issn-type":[{"type":"electronic","value":"2296-2565"}],"subject":[],"published":{"date-parts":[[2025,7,16]]},"article-number":"1611459"}}